# AveXis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avexis

- Industry: Biotechnology
- Headquarters: Bannockburn, US
- Website: www.avexis.com
- Total disclosed funding: $75M
- Latest round: Series D (Sep 8, 2015)
- Investors on record: 12

## About

AveXis, Inc. is a biotechnology company focused on developing innovative gene therapies for the treatment of rare neurological diseases, aiming to transform patient care and improve quality of life.Founded in 2010 in Bannockburn, US, AveXis specializes in gene therapy solutions for spinal muscular atrophy and other conditions. In February 2016, the company raised USD 95 mn by offering shares. In April 2018, Novartis AG acquired AveXis for USD 8.7 bn. Doris Philips serves as CEO.AveXis develops gene therapies targeting severe neurological disorders, including its flagship product Zolgensma®, designed for spinal muscular atrophy. These therapies are distributed globally and aim to address critical health challenges, improving care for patients with complex medical needs.In 2017, AveXis reported a revenue of USD 0, with an EBITDA of USD -218,097,000.AveXis plans to expand its product portfolio with upcoming gene therapies targeting additional rare diseases. The company intends to penetrate new markets in Europe and Asia by 2020. The recent acquisition by Novartis will enhance its capabilities to fund these initiatives, ensuring broader access to its innovative therapies.

## Funding rounds

- Series D, Sep 8, 2015, $65M — T Rowe Price, Venrock, Adage Capital Management, Roche Venture Fund, Foresite Capital, QVT funds, Deerfield Management, RTW Investments, RA Capital Management, Rock Springs Capital, Janus Henderson Investors, Boxer Capital
- Series C, Jan 9, 2015, $10M — Roche Venture Fund, Deerfield Management

## Investors

- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series C, Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C, Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series D
- Adage Capital Management — Series D
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series D
- QVT funds — Series D
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Rock Springs Capital — Series D
- Janus Henderson Investors — Series D
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series D